The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO
dc.contributor.author | Collins, P | en_US |
dc.contributor.author | Chalmers, E | en_US |
dc.contributor.author | Chowdary, P | en_US |
dc.contributor.author | Keeling, D | en_US |
dc.contributor.author | Mathias, M | en_US |
dc.contributor.author | O'Donnell, J | en_US |
dc.contributor.author | Pasi, KJ | en_US |
dc.contributor.author | Rangarajan, S | en_US |
dc.contributor.author | Thomas, A | en_US |
dc.date.accessioned | 2016-07-20T10:58:10Z | |
dc.date.available | 2016-05-12 | en_US |
dc.date.issued | 2016-07 | en_US |
dc.date.submitted | 2016-06-21T11:41:48.203Z | |
dc.identifier.issn | 1351-8216 | en_US |
dc.identifier.other | 10.1111/hae.13013 | |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/13576 | |
dc.format.extent | 487 - 498 | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | HAEMOPHILIA | en_US |
dc.subject | coagulation factor concentrates | en_US |
dc.subject | enhanced half-life | en_US |
dc.subject | pharmacokinetics | en_US |
dc.subject | prophylaxis | en_US |
dc.title | The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO | en_US |
dc.type | Article | |
dc.rights.holder | 2016 John Wiley & Sons Ltd | |
dc.identifier.doi | 10.1111/hae.13013 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387387000026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 4 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 22 | en_US |
Files in this item
This item appears in the following Collection(s)
-
Centre for Immunobiology [1122]